Integrity,Innovation,Reliability,Responsibility

Hinova Pharmaceuticals' Prostate Cancer Product Deutenzalutamide Research Published in Renowned SCI Journal STTT

Time:2026-04-15 Source:海创药业 Hits:119

Recently, the Phase III clinical trial results (HC-1119-04) of Deutenzalutamide, a Class 1 new drug developed by Hinova Pharmaceuticals Co., Ltd. (hereinafter referred to as "the Company"), were published in the internationally renowned SCI journal Signal Transduction and Targeted Therapy (STTT), under the title "Deutenzalutamide, a novel androgen receptor inhibitor, after progression on docetaxel and abiraterone in metastatic castration-resistant prostate cancer: results from the randomized phase III HC-1119-04 trial."


Prostate cancer is one of the most common malignant tumors in the male genitourinary system and has become a significant public health issue threatening men's health in China. Metastatic castration-resistant prostate cancer (mCRPC), as the terminal stage of disease progression, carries a poor prognosis and limited overall survival. As the number of treatment lines increases, therapeutic options become scarce, and the complexity of clinical management rises significantly.


For patients who experience disease progression after prior treatment with docetaxel chemotherapy and androgen receptor signaling inhibitors (ARSI, such as abiraterone and enzalutamide), current clinical practice faces multiple challenges. On one hand, persistent abnormal activation of the AR signaling pathway drives tumor progression, and traditional sequential ARPI therapy exhibits significant cross-resistance with limited efficacy. On the other hand, patients often suffer from declining physical performance status and accumulated long-term treatment-related toxicities, further limiting subsequent treatment options. Consequently, the "post-docetaxel/post-ARSI" population lacks standard treatment regimens that balance efficacy and safety, representing a prominent unmet clinical need.


As a next-generation deuterated androgen receptor inhibitor, Deutenzalutamide retains potent inhibition of the AR signaling pathway while optimizing pharmacokinetic properties through deuterium modification. This delays drug metabolism, improves the profile of active metabolites, and reduces central nervous system (CNS) exposure, thereby potentially enhancing safety and tolerability while maintaining efficacy.


The HC-1119-04 study, a randomized, double-blind, placebo-controlled Phase III clinical trial, systematically evaluated the efficacy and safety of Deutenzalutamide for the first time in mCRPC patients who had previously failed abiraterone treatment, with some having also received docetaxel. The results demonstrated that Deutenzalutamide significantly prolonged radiographic progression-free survival (rPFS) (HR=0.58, reducing the risk of disease progression or death by 42%), clearly confirming its antitumor activity in this heavily pretreated population. Meanwhile, after correcting for the interference of subsequent anticancer treatments, overall survival (OS) also showed a trend toward benefit, further supporting its clinical value. In terms of safety, no obvious CNS-related serious adverse events were observed, indicating good tolerability in this population.


Prostate cancer is one of the most common malignant tumors in the male genitourinary system and has become a significant public health issue threatening men's health in China. Metastatic castration-resistant prostate cancer (mCRPC), representing the terminal stage of disease progression, is associated with a poor prognosis and limited overall survival. As the number of treatment lines increases, therapeutic options become scarce, and the complexity of clinical management rises significantly.


For patients who experience disease progression despite prior treatment with docetaxel chemotherapy and androgen receptor signaling inhibitors (ARSI, such as abiraterone and enzalutamide), current clinical practice faces multiple challenges. On one hand, persistent abnormal activation of the AR signaling pathway drives tumor progression, and traditional sequential ARPI therapy exhibits significant cross-resistance with limited efficacy. On the other hand, patients often suffer from declining physical performance status and accumulated long-term treatment-related toxicities, which further limit subsequent treatment options. Consequently, the "post-docetaxel/post-ARSI" population lacks standard treatment regimens that balance efficacy and safety, representing a prominent unmet clinical need.


As a next-generation deuterated androgen receptor inhibitor, Deutenzalutamide retains potent inhibition of the AR signaling pathway while optimizing pharmacokinetic properties through deuterium modification. This delays drug metabolism, improves the profile of active metabolites, and reduces central nervous system (CNS) exposure, thereby potentially enhancing safety and tolerability while maintaining efficacy.


The HC-1119-04 study, a randomized, double-blind, placebo-controlled Phase III clinical trial, systematically evaluated the efficacy and safety of Deutenzalutamide for the first time in mCRPC patients who had previously failed abiraterone treatment, with some having also received docetaxel. The results demonstrated that Deutenzalutamide significantly prolonged radiographic progression-free survival (rPFS) (HR=0.58, reducing the risk of disease progression or death by 42%), clearly confirming its antitumor activity in this heavily pretreated population. Meanwhile, after correcting for the interference of subsequent anticancer treatments, overall survival (OS) also showed a trend toward benefit, further supporting its clinical value. In terms of safety, no obvious CNS-related serious adverse events were observed, indicating good tolerability in this population.